A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH

PHASE2CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

May 15, 2023

Study Completion Date

January 26, 2024

Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
DRUG

VK2809

Capsule

DRUG

Placebos

Capsule

Trial Locations (79)

1070

Viking Clinical Site 502, Brussels

3000

Viking Clinical Site 503, Brussels

10033

Viking Clinical Site 152, New York

14642

Viking Clinical Site 128, Rochester

15213

Viking Clinical Site 311, Pittsburgh

19107

Viking Clinical Site 148, Philadelphia

20770

Viking Clinical Site 107, Greenbelt

21202

Viking Clinical Site 109, Baltimore

23249

Viking Clinical Site 209, Richmond

23298

Viking Clinical Site 312, Richmond

23602

Viking Clinical Site 304, Newport News

27514

Viking Clinical Site 314, Chapel Hill

27710

Viking Clinical Site 116, Durham

28027

Viking Clinical Site 126, Concord

28557

Viking Clinical Site 153, Morehead City

29605

Viking Clinical Site 127, Greenville

30060

Viking Clinical Site 111, Marietta

30309

Viking Clinical Site 144, Atlanta

32127

Viking Clinical Site 215, Port Orange

32503

Viking Clinical Site 131, Pensacola

33014

Viking Clinical Site 106, Miami

33016

Viking Clinical Site 221, Miami Lakes

33136

Viking Clinical Site 301, Miami

Viking Clinical Site 310, Miami

34208

Viking Clinical Site 226, Bradenton

34211

Viking Clinical Site 150, Lakewood Rch

34240

Viking Clinical Site 218, Sarasota

35758

Viking Clinical Site 105, Madison

37040

Viking Clinical Site 227, Clarksville

37076

Viking Clinical Site 118, Hermitage

38700

Viking Clinical Site 610, Grenoble

39216

Viking Clinical Site 213, Jackson

39670

Viking Clinical Site 401, Acapulco de Juárez

45249

Viking Clinical Site 137, Cincinnati

46202

Viking Clinical Site 120, Indianapolis

46635

Viking Clinical Site 130, South Bend

48109

Viking Clinical Site 158, Ann Arbor

48202

Viking Clinical Site 133, Detroit

50265

Viking Clinical Site 211, West Des Moines

64000

Viking Clinical Site 422, Monterrey

64111

Viking Clinical Site 112, Kansas City

64131

Viking Clinical Site 217, Kansas City

66606

Viking Clinical Site 145, Topeka

70072

Viking Clinical Site 146, Marrero

70112

Viking Clinical Site 307, New Orleans

71291

Viking Clinical Site 166, West Monroe

72117

Viking Clinical Site 214, North Little Rock

75012

Viking Clinical Site 607, Paris

75013

Viking Clinical Site 603, Paris

75203

Viking Clinical Site 113, Dallas

76012

Viking Clinical Site 115, Arlington

77030

Viking Clinical Site 142, Houston

78215

Viking Clinical Site 102, San Antonio

78229

Viking Clinical Site 101, San Antonio

Viking Clinical Site 143, San Antonio

Viking Clinical Site 201, San Antonio

78539

Viking Clinical Site 220, Edinburg

80054

Viking Clinical Site 611, Amiens

84405

Viking Clinical Site 224, Ogden

85306

Viking Clinical Site 216, Glendale

85712

Viking Clinical Site 159, Tucson

89106

Viking Clinical Site 160, Las Vegas

89511

Viking Clinical Site 223, Reno

91105

Viking Clinical Site 125, Pasadena

91402

Viking Clinical Site 205, Panorama City

91736

Viking Clinical Site 134, Montclair

92037

Viking Clinical Site 302, La Jolla

Viking Clinical Site 121, San Diego

92377

Viking Clinical Site 110, Rialto

93701

Viking Clinical Site 161, Fresno

93720

Viking Clinical Site 208, Fresno

94000

Viking Clinical Site 612, Créteil

94115

Viking Clinical Site 103, San Francisco

95817

Viking Clinical Site 117, Sacramento

98105

Viking Clinical Site 317, Seattle

06510

Viking Clinical Site 156, New Haven

02111

Viking Clinical Site 147, Boston

06700

Viking Clinical Site 421, Mexico City

00927

Viking Clinical Site 219, San Juan

All Listed Sponsors
lead

Viking Therapeutics, Inc.

INDUSTRY

NCT04173065 - A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH | Biotech Hunter | Biotech Hunter